- In August 2023, CVS Health launched Cordavis, a wholly owned subsidiary dedicated to the co-production and commercialization of biosimilar medicines. By collaborating with manufacturers, Cordavis aims to provide FDA-approved biosimilars that are high in quality, easy for patients to use, and ensure a stable, long-term supply of affordable medicines for the U.S. pharmaceutical market
- In July 2023, according to the World Health Organization (WHO), there were 39 million global cases of HIV reported in 2022, leading to 630,000 HIV-related deaths. These statistics emphasize the ongoing global health challenge posed by HIV/AIDS, highlighting the critical need for comprehensive prevention, treatment, and support programs to address the disease's impact
- In June 2022, Apex Laboratories, an Indian pharmaceutical company, introduced an advanced version of Itraconazole Capsules Supra Bioavailable in 65 and 130 mg dosages. These capsules offer improved bioavailability, delivering 90% of the active drug with a reduced dosage. This innovation enhances the effectiveness of treatment for fungal infections such as blastomycosis, histoplasmosis, and aspergillosis
- In April 2021, Pfizer Inc., a leading U.S.-based pharmaceutical and biotechnology company, acquired Amplyx Pharmaceuticals Inc. to strengthen its anti-infective portfolio. This acquisition expands Pfizer’s expertise in treating infectious diseases, signaling its commitment to advancing solutions in the field of anti-infectives. The deal enables Pfizer to enhance its offerings and research capabilities in this domain
